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ABSTRACT
Background: Sarcopenia is defined as loss of muscle mass with attendant loss of muscle strength 
and physical function and is associated with advancing age. Inflammatory condition of chronic 
disease leads to more rapid progression of this syndrome, which may adversely affect quality 
of life. The aim of this study was to determine the relationship between chronic obstructive 
pulmonary disease (COPD) and sarcopenia. Methods: This study included 108 COPD patients 
who were treated in the pulmonary clinic at Masih Daneshvari Hospital. Patients were categorized 
into three groups based on Global Initiative for Obstructive Lung Disease criteria. Sarcopenic 
parameters including muscle mass, muscle strength, and physical performance were measured by 
Bioimpedance Analysis, hand grip dynamometer, and the Short Physical Performance Battery test, 
respectively. According to the European Working Group on Sarcopenia in Older People cutoff 
points and the definition of sarcopenic obesity, sarcopenic patients were diagnosed and categorized 
based on different COPD severity scores. Results: The relationship between sarcopenia and COPD 
grading, which was assessed using multiple regression models with adjustment of confounding 
factors, including age, chronic diseases, and smoking, was statistically insignificant. However, by 
using forced expiratory volume in 1 second (FEV1) or ratio of FEV1 to forced vital capacity in 
this model, the results were significant (P = 0.026). A positive linear correlation was observed 
between skeletal muscle index (SMI) and spirometric data, which was assessed by Spearman’s 
correlation test. By exploring the association between sarcopenia and obesity with the one-way 
analysis of variance test, sarcopenic patients represented to have the minimal spirometric measures. 
However, this difference was only significant for actual measurements. Conclusion: This study 
showed that sarcopenic COPD patients had smaller spirometric measurements and that 
sarcopenia and magnitude of SMI were positively correlated with obstruction severity.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a chronic 
disease associated with several systemic and pulmonary co-
morbidities. In particular, loss of muscle mass is a principal 
comorbidity that is frequently observed in COPD patients 
(1-3) and results from several factors, including improper 
nutrition, chronic use of corticosteroids, and systemic in-
flammatory mediators (4). Additionally, muscle depletion 
may adversely affect respiratory muscle function and exer-
cise capacity and may even increase mortality (5-7).
In 1989,(8) sarcopenia was defined as age-related loss 
of skeletal muscle mass; however, it now indicates any de-
pletion of muscle mass that occurs with aging and with any 
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condition, such as chronic disease including COPD, which 
causes a catabolic state (9,10). Loss of muscle can begin at 
age 35 and accelerates with increasing age (11,12). Although 
sarcopenia is known as a geriatric syndrome, it can occur in 
young people after chronic disease and from malnutrition as 
well. Sarcopenia characterized by depletion of muscle mass 
is a common feature of all chronic diseases that are accom-
panied by inflammation; moreover, it can be associated with 
preserved fat mass that leads to a specific body composition 
state known as sarcopenic obesity. Koo and colleagues (13) 
showed that the COPD patients with sarcopenic obesity pre-
sented with the lowest pulmonary function test parameters, 
yet they had a better quality of life compared to patients who 
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experienced other body composition changes. Although this 
syndrome has attracted considerable interest, as yet it has no 
universally accepted definition. However, the description of 
this syndrome by the European Working Group on Sarco-
penia in Older People (EWGSOP) as loss of muscle mass 
accompanied by one of two other elements of physical func-
tion and muscle strength is most commonly used in research 
settings. Early identification of sarcopenia and sarcopenic 
obesity would enable appropriate preventive and therapeutic 
interventions.
To date, most have studies examined body mass index 
(BMI) and fat-free mass in COPD patients (14-17). To our 
knowledge, ours is the first to study both the quantity (mus-
cle mass) and the quality (muscle strength and physical per-
formance) aspects of sarcopenia in COPD patients.
In this study, we hypothesized that the chances of COPD 
patients developing sarcopenia increase with the severity of 
the disease. Also, we measured the prevalence of sarcope-
nia in COPD patients and comprehensively investigated lean 
body mass in relation to different lung function indexes.
METHODS
This cross-sectional study included 108 stable COPD patients 
who were seen for follow-up from April to August 2015 at 
the pulmonary clinic of Masih Daneshvari Hospital in Teh-
ran, Iran. Written and informed consent was obtained from 
all patients, and the ethics committee of Masih Daneshvari 
Hospital approved this study. Basic information, including 
age, smoking history, other comorbidities (e.g. other chronic 
diseases), last hospital admission, severity of dyspnea (by the 
Medical Research Council [MRC] dyspnea scale) (18), and 
medication history, were obtained from patient records. If 
patients were experiencing an exacerbation of COPD or had 
any sign or symptom of systemic infection, they were exclud-
ed from the study. Additionally, because very few women 
presented at the clinic at the time, women were also excluded.
All patients underwent spirometry during their last vis-
it. Based on their spirometric results, they were categorized 
according to Global Initiative for Obstructive Lung Disease 
(GOLD) guidelines (19) into mild, moderate, and severe/
very severe groups. Spirometry was conducted according to 
American Thoracic Society guidelines (20); pneumotacho-
graph (Master Lab, E. Jaeger, Würzburg, Germany) results 
and all parameters were recorded as percentage of predicted 
and actual measurements.
Muscle mass measurements were taken using a Bio-
impedance Analyzer (body mass analyzer, model 359. 
GAIA, Jawon, Korea) in the standard condition based on 
National Institutes of Health guidelines (21). Patients with 
pacemakers were excluded from the study. Skeletal muscle 
index (SMI) was calculated as appendicular muscle mass 
(kg) divided by height squared (m2). Appendicular muscle 
mass was calculated as the sum of the lean soft tissue of 
four limbs. Based on EWGSOP recommendations, muscle 
mass index less than 8.87 was considered a cutoff point for 
sarcopenia.
Patients were classified as underweight if their BMI 
was less than 21 kg/m2; they were classified as normal 
weight if their BMI was between 21 kg/m2 and 25 kg/m2; 
they were classified as overweight if their BMI was great-
er than or equal to 25 kg/m2 and less than 30 kg/m2; and 
they were classified as obese if their BMI was greater than 
30 kg/m2 (22).
Grip strength in the dominant hand as an indicator of 
muscle strength was measured using a dynamometer (model 
DHD-3, GH1003, Sachon, Korea), based on American So-
ciety of Hand Therapists protocols (23). The test was per-
formed three times in 20-second intervals, and the highest 
measurement was recorded. Measurements lower than 30 
were considered as reference value for sarcopenia.
To examine physical function, we evaluated patients 
using the Short Physical Performance Battery (SPPB) test. 
This test assesses balance, gait, strength, and endurance by 
examining individuals’ ability to stand with their feet to-
gether in side-by-side, semi-tandem, and tandem positions; 
time to rise from a seated position five times; and time to 
walk 8 feet (24). Each part of the test has four scores, and 
the maximum score for the whole test is 12. Scores were 
calculated based on the time needed to complete each part 
of the test.
Patients were considered to have sarcopenia according 
to EWGSOP guidelines if they had an SMI less than 8.87 
plus at least one grip strength or SPPB test measurement less 
than the cutoff point determined for sarcopenia. They were 
considered sarcopenically obese if, in addition to being sar-
copenic, their BMI was greater than 25 kg/m2.
To begin, we analyzed the distribution of study variables. 
All continuous variables are presented as mean ± standard 
deviation (SD), and categorical variables are presented as 
frequency (%). Comparison between variables was deter-
mined by an unpaired t-test, Fisher’s exact test, and the chi-
squared test, when appropriate. The Mann-Whitney test was 
used to compare dyspnea function class in four groups that 
were categorized based on obesity and sarcopenic status.
Significant variables were introduced in a multiple re-
gression model to determine development of sarcopenia in 
relation to lung function values.
One-way analysis of variance (ANOVA) and Krus-
kal-Wallis tests were used to determine differences in spi-
rometric parameters, BMIs, and MRC scores in four groups 
of patients with various obesity and sarcopenia statuses and 
with different stages of COPD. A post-hoc test was used for 
multiple comparisons between groups.
Pearson correlations were evaluated between SMI and 
BMI and pulmonary function variables after checking for 
normal distribution of SMI and BMI. Correlation between 
dyspnea severity and measures of SMI and BMI were as-
sessed using Spearman’s correlation bivariate test.
P values less than 0.05 were considered statistically sig-
nificant. Statistical analyses were performed using SPSS 
version 23 software.
RESULTS
All 108 patients met the inclusion criteria. Their mean age was 
60.7 years (SD, 11.13). Following the proportions recommend-
ed by the GOLD guidelines, 28 patients (25.9%) comprised 
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the mild COPD group, 44 patients (40.7%) comprised the 
moderate COPD group, and 36 patients (33.3%) comprised the 
severe/very severe COPD group. Of the patients, 55 (50.9%) 
were active smokers, 16 (14.8%) were former smokers, and 
the rest were exposed to secondhand smoke. Thirty-six (33%) 
of 108 patients were identified as having sarcopenia. Detailed 
clinical characteristics and test parameter measurements of pa-
tients with and without sarcopenia are outlined in Table 1.
The correlation between SMI and spirometric parameters 
is presented in Table 2. SMI was weakly but significantly 
correlated with parameters of diffusion capacity; however, 
when we assessed SMI in different COPD GOLD stages, it 
did not reach statistical significance (P = 0.067). Addition-
ally, there was negative correlation between SMI and MRC 
scores using Spearman’s correlation test, although the results 
were not significant (P = 0.058).
As shown in Table 1, no significant relation was observed 
between COPD stage and whether a patient developed sar-
copenia (P = 0.65). Therefore, to assess the relation between 
sarcopenia and COPD severity further and also because of the 
high correlation of SMI with parameters of lung diffusion, we 
used a multiple regression analysis model with sarcopenia as 
a dependent variable and adjusted for age, smoking status, 
and chronic disease as contributing factors (Table 3).
Patients’ mean BMI was 25.6 kg/m2 (SD, 5.31). The 
proportion of each subtype of BMI, including underweight, 
normal, overweight, and obese, was 17 (15.7%), 55 (59%), 
28 (25.9%), and 8 (7.4%), respectively. Patients with moder-
ate severity COPD had the highest BMI (27.15+-5.6; P = 0.02) 
compared to the BMI of patients with mild and severe/very 
severe COPD (25.31+-5.36 and 23.97+-4.36, respectively). 
Patients with sarcopenia tended to have normal weight com-
pared to patients who did not have sarcopenia, of whom most 
were overweight. As shown in Table 2, positive correlation 
was significant only between actual measures of pulmonary 
function parameters and BMI. Patients were compared in 
four groups: 1) non-sarcopenic non-obese(S-O-); 2) sarco-
penic non-obese (S+O-); 3) obese non-sarcopenic(S-O+); 
and 4) sarcopenic obese(S+O+) (Table 4). They were also 
compared in post-hoc analyses to evaluate the differences 
between the actual number of spirometric parameters, which 
was significant in the ANOVA test (Table 4). The difference 
between S-O+ and S+O+ and the difference between S-O+ 
and S+O- was significant for forced vital capacity (FVC), 
forced expiratory volume in 1 second (FEV1), and ratio of 
FEV1 to FVC (FEV1%) values.
DISCUSSION
In this study, 34% of COPD patients were sarcopenic. As we 
investigated the prevalence of sarcopenia in different stages 
of COPD based on GOLD guidelines, we found no signifi-
cant difference between groups, but we did find that pulmo-
nary function values were significantly worse in sarcopenic 
patients. Although we found that sarcopenia status, deplet-
ed muscle mass, and reduced BMI were associated with 
decreased diffusion pulmonary indexes, these associations 
were mainly in relation to the actual value of pulmonary 
function parameters rather than percent of predicted values.
Additionally, we found that higher BMI and higher 
SMI were both associated with better pulmonary function 
values and worse lung diffusion indexes in sarcopenic 
obese patients. However, we found significant differences 
only between sarcopenic and obese patients and between 
Table 1. Patient characteristics (N=108)
Non‑Sarcopenia
N=72
Sarcopenia
N=36
P‑value
Age (SD) 59.00 (10.52) 64.33 (11.61) 0.018
BIA outcome (SD)
Weight, kg 77.79 (14.48) 57.11 (8.41) <0.001
PBF 23.10 (7.86) 20.36 (11.28) 0.022
SLM/Ht 10.14 (2.58) 8.07 (0.51) <0.001
Hand grip, kg (SD) 30.93 (7.51) 24.07 (5.39) <0.001
SPPB score (SD) 11.35 (0.84) 10.33 (2.16)
GOLD stage (%) 0.66
Mild 20 (27.8) 8 (22.2)
Moderate 30 (41.7) 14 (38.9)
Severe/very severe 22 (30.6) 14 (38.9)
Dyspnea FC (%) 0.65
 1and 2 41 (57.8) 17 (45.2)
3 and 4 30 (42.2) 19 (52.8)
Smoking YP (SD) 24.30 (30.77) 26.29 (28.05) 0.57
Chronic disease (%) 30 (41.7) 9 (25) 0.089
BMI (SD) 27.61 (5.05) 21.64 (3.22) <0.001
Type of BMI (%) <0.001
Underweight 2 (2.8) 7 (19.4) 
Normal weight 18 (25) 22 (61.1)
Overweight 36 (50) 7 (19.4)
Obese 16 (22.2) 0 (0)
GOLD: Global Initiative for Chronic Lung Disease; SD: Standard 
deviation; PBF: Percent body fat; SLM: Soft lean mass; SPPB: Short 
physical performance battery; FC: Function class; YP: Year pack; 
BMI: Body mass index
Table 2. Pearson bivariate correlation coefficient of SMI 
and BMI with spirometric variables (N=108)
Variable SMI P‑value BMI P‑value
FVC
Predicted 0.08 0.399 0.115 0.23
Actual 0.305 <0.001 0.22 0.02
FEV1%
Predicted 0.225 0.02 0.23 0.01
Actual 0.228 0.018 0.26 0.006
FEV1
Predicted 0.123 0.209 0.15 0.11
Actual 0.319 <0.001 0.23 0.01
Dyspnea (FC) 0.184 0.058 -0.115 0.23
FVC: Forced vital capacity; FEV1,: Forced expiratory volume 
in 1 second; FEV1%: ratio of FEV1 to FVC; FC: Function class; 
SMI: Skeletal muscle index; BMI: Body mass index
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Table 3. Multiple regression analysis with sarcopenia as a dependent variable
(95% CI) Sarcopenia Non‑sarcopenia P‑value* ≤ Adjusted OR
FVC (SD)
Actual 1.95 (0.99) 2.9 (1.15) 0.002 1.99 (1.16-3.4)*
Predicted 63.22 (24.56) 75.54 (22.07) 0.047 1.02 (0.99-1.04)
FEV1 (SD)
Actual 1.39 (0.77) 1.95 (0.99) 0.002 2.11 (1.11-4)*
Predicted 52.72 (22.9) 63.22 (24.56) 0.035 1.021 (1-1.04)*
FEV1% (SD)
Actual 60.10 (11.75) 64.83 (11.50) 0.048 1.03 (0.99-1.07)
Predicted 78.78 (15.54) 84.43 (16.50) 0.084 1.02 (0.99-1.056)
SD: Standard deviation; FVC: Forced expiratory volume; FEV1: Forced expiratory volume in first second; FEV1%: ratio of FEV1 to FVC; OR: Odds 
ratio; CI: Confidence interval
*P values<0.05 are statistically significant ≤: variables include chronic disease, age, and smoking
Table 4. Patients in four groups compared based on their BMI and sarcopenia status
S‑O‑ S‑O+ S‑O‑ S+O+ P‑value
COPD %) 0.114
Mild 5 (25) 15 (28.8) 8 (27.6) 0 (0)
Moderate 0 (0)
Severe/very 3 (15) 27 (51.9) 9 (31) 5 (71.4)
Severe 12 (60) 10 (19.2) 12 (41.4) 2 (28.6)
FVC (SD)
Actual 2.7 (1.15) 2.9 (1.15) 2.29 (0.92) 1.94 (0.67) 0.016
Predicted 70.05 (21.7) 77.23 (22.08) 67.07 (22.6) 65.25 (13.86) 0.148
FEV1% (SD)
Actual 59.52 (15.53 66.46 (9.52) 60.8 (12.15) 57.66 (10.57) 0.029
Predicted 79.7 (23.54) 85.89 (13.57) 79.32 (15.11) 76.87 (13.06) 0.167
FEV1 (SD)
Actual 1.79 (1.16) 2 (0.93) 1.47 (0.83) 1.08 (0.3) 0.017
Predicted 55.41 (26.8) 65.63 (23.56) 54.1 (25.34) 47.87 (10.42) 0.066
Dyspnea FC (%) 0.37
1 2 (10) 6 (11.8) 2 (6.9) 1 (14.3)
2 8 (40) 25 (49) 13 (44.8) 1 (14.3)
3 7 (35) 19 (37.3) 11 (37.9) 4 (57.1)
4 3 (15) 1 (2) 3 (10.3) 1 (14.3)
SD: Standard deviation; FVC: Forced vital capacity; FEV1:  Forced expiratory volume in first second; FEV1%: ratio of FEV1 to FVC; FC: Function 
class; S-O, no sarcopenia, no obesity; S+O-, sarcopenia, no obesity; S+O+, sarcopenia, obesity; S-O+, no sarcopenia, obesity
sarcopenic and sarcopenic obese patients. This may indi-
cate that soft lean mass provides information beyond BMI 
in predicting disease severity, although further studies are 
needed to investigate SMI and BMI separately for this pur-
pose.
A previous study by Ischaki and colleagues (25) found 
that, based on GOLD staging and spirometric values, SMI 
was the only measurement related to COPD severity. Fur-
thermore, this study found no relationship between BMI 
and disease severity indexes. Although in our study SMI 
correlated with the same spirometric parameters as shown 
in older studies (25,26), we could not demonstrate that SMI 
was reduced as COPD stage progressed.
Like the results reported in other studies (27,28), we 
found no significant relationship between SMI and dyspnea 
severity (expressed by MRC scores), which indicates that 
dyspnea is probably affected by factors other than muscle 
mass alone.
Our results are in line with the results reported in a study 
of Korean COPD patients (29), which also assessed patients 
in four groups with different obesity and sarcopenia status-
es. In both studies, sarcopenic obese patients presented with 
the lowest spirometric parameters; however, differences 
between categories were also significant for FEV1% in our 
study, which was not found in the Korean study. Addition-
ally, in the study of the Korean patients, the investigators 
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found that the difference between groups with the same obe-
sity status and different sarcopenia status for all pulmonary 
function parameters was significant, whereas in our study 
reduction in pulmonary function values was significant be-
tween sarcopenic category and obese and sarcopenic obese 
patients. This difference between studies could be explained 
by different definitions of sarcopenia.
In our study, we considered both the qualitative and 
quantitative aspects of sarcopenia in COPD patients, which 
sets our study apart from previous studies. Nevertheless, our 
study has some limitations. First, since the number of wom-
en who met the inclusion criteria was small, women were 
excluded in our study, so we cannot extrapolate our study 
results to the general population of COPD patients. Sec-
ond, we did not perform dual-energy X-ray absorptiometry, 
which is the best clinically available technique to measure 
lean muscle mass and fat mass. Third, for the diagnosis of 
sarcopenia, we used the EWGSOP cutoff point, which might 
need to be modified for Asian populations.
CONCLUSION
We conclude that spirometric indexes, specifically actual 
measurements, are better predictors of whether COPD pa-
tients will develop sarcopenia than GOLD staging of this 
disease. Sarcopenia and obesity have independent effects in 
pulmonary function values, and we recommend that both of 
these elements be assessed in all COPD patients.
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